Working… Menu
Trial record 8 of 151 for:    Ipratropium OR atrovent

Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02236715
Recruitment Status : Completed
First Posted : September 11, 2014
Last Update Posted : September 11, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Condition or disease Intervention/treatment
Pulmonary Disease, Chronic Obstructive Drug: Atrovent®

Layout table for study information
Study Type : Observational
Actual Enrollment : 1039 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Unit Dose Vial 500 µg in Chronic Obstructive Airways Disease
Study Start Date : September 1999
Actual Primary Completion Date : February 2000

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD

Group/Cohort Intervention/treatment
Chronic Obstructive Airways Disease Drug: Atrovent®

Primary Outcome Measures :
  1. Change in total severity of the clinical picture rated on a 4-point scale [ Time Frame: after 4 weeks ]

Secondary Outcome Measures :
  1. Assessment of efficacy by investigator on a 4-point scale [ Time Frame: after 4 weeks ]
  2. Assessment of efficacy by patient on a 4-point scale [ Time Frame: after 4 weeks ]
  3. Assessment of tolerability by investigator on a 4-point scale [ Time Frame: after 4 weeks ]
  4. Assessment of tolerability by patient on a 4-point scale [ Time Frame: after 4 weeks ]
  5. Number of patients with adverse drug reactions [ Time Frame: up to 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with chronic obstructive airways disease recruited at general practitioners, pneumologists, internists

Inclusion Criteria:

  • Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease
  • Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion Criteria:

  • Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02236715     History of Changes
Other Study ID Numbers: 244.2493
First Posted: September 11, 2014    Key Record Dates
Last Update Posted: September 11, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action